Welcome to the international HTA database

Showing [23383 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2009	Medical Advisory Secretariat (MAS)	Oral appliances for obstructive sleep apnea: an evidence-based analysis
2009	NIHR Health Technology Assessment programme	Adalimumab for the treatment of moderate to severe psoriatic arthritis
2009	Committee for New Health Technology Assessment (CNHTA)	[AMH]
2009	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Assessment of the re-designed diagnosis process for colorectal cancer]
2009	Medical Advisory Secretariat (MAS)	Fenestrated endovascular grafts for the repair of juxtarenal aortic aneurysms: an evidence-based analysis
2009	Committee for New Health Technology Assessment (CNHTA)	[Genotyping of MDM2 SNP309 polymorphism]
2009	Medical Advisory Secretariat (MAS)	OHTAC 2009 Progress Report - advancing health: evidence-based advice on health technology
2009	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Efficacy and safety of 64-multislice CT: a systematic review]
2009	Medical Advisory Secretariat (MAS)	Intrastromal corneal ring implants for corneal thinning disorders: an evidence-based analysis
2009	Committee for New Health Technology Assessment (CNHTA)	[ERCC1 RNA RT-PCR quantification]
2009	Quality Improvement Scotland (NHS QIS )	Is patient self-monitoring (including self-testing and selfmanagement) of oral anticoagulation therapy safe, efficacious and cost-effective?
2009	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Standards for the appropriate use of health technologies. Pharmacological treatment of bipolar disorder]
2009	Penn Medicine Center for Evidence-based Practice (CEP)	Early term induction of labor
2009	Committee for New Health Technology Assessment (CNHTA)	[RRM1 RNA RT-PCR quantification]
2009	Quality Improvement Scotland (NHS QIS )	Provision of information to patients with long term conditions
2009	Committee for New Health Technology Assessment (CNHTA)	[Balloon tamponade for postpartum hemorrhage]
2009	Quality Improvement Scotland (NHS QIS )	A systematic narrative review of quality improvement models in health care
2009	HAYES, Inc.	Intravitreal bevacizumab (Avastin; Genentech Inc.) for the treatment of proliferative diabetic retinopathy
2009	Committee for New Health Technology Assessment (CNHTA)	[Endobronchial ultrasound/fine needle aspiration]
2009	Quality Improvement Scotland (NHS QIS )	Clinical and cost-effectiveness of self-monitoring of blood glucose (SMBG) for non-insulin treated type 2 diabetes
2009	VA Technology Assessment Program (VATAP)	Systematic reviews for localized prostate cancer
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Cost-effectiveness of two different strategies to implement the NVOG guideline programme on subfertility]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Is biomedical research a good social investment? The evaluation of the social impact of medical research
2009	HAYES, Inc.	Breast-specific gamma imaging (BSGI)
2009	Committee for New Health Technology Assessment (CNHTA)	[SurePATH liquid-based cytology test for FNA(fine needle aspiration) specimens]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Multiple chemical hypersensibility: state of the art on aetiology and treatment
2009	Committee for New Health Technology Assessment (CNHTA)	[Antroduodenal manometry]
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Darunavir (Prezista®) for the treatment of HIV-1 infected, treatment-naïve adults in combination with other antiretroviral medicinal products
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Costs and effects of two modes for disease management of chronic obstructive pulmonary disease (COPD) in general practice. A randomized controlled trial comparing regular nurse practitioner review and self-management education]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Amotosalen (Intercept) for the inactivation of pathogens in plasma and platelets: usage in Spain
2009	HAYES, Inc.	Laparoscopic ileal interposition and sleeve gastrectomy for treatment of type 2 diabetes [REVISED 02.16.09]
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Degarelix (Firmagon®) for the treatment of advanced hormone-dependent prostate cancer
2009	HAYES, Inc.	Amyotrophic Lateral Sclerosis (ALS; Lou Gehrig Disease)
2009	Penn Medicine Center for Evidence-based Practice (CEP)	Reprocessing of surgical drills
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Development of organizational interventions to improve compliance with guidelines on depression and anxiety in primary care]
2009	Penn Medicine Center for Evidence-based Practice (CEP)	Managing the difficult airway
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Ranolazine (Ranexa®) as add-on therapy for symptomatic treatment of stable angina pectoris
2009	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Emerging technologies (part 2): EU newsletter
2009	HAYES, Inc.	Laparoscopic sleeve gastrectomy for super obesity in adults
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Methoxy polyethylene glycol-epoetin beta (Mircera®)
2009	National Evidence-based Healthcare Collaborating Agency (NECA)	[Reuse of single-use medical devices: current evidence and regulations]
2009	HAYES, Inc.	Breast cancer susceptibility 1 and 2 (BRCA1/2) sequence variant testing for susceptibility to hereditary breast cancer
2009	Agency for Healthcare Research and Quality (AHRQ)	Impact of consumer health informatics applications
2009	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Information and communications technologies in CHF management programmes. Organizational challenges and evidence status]
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Mecasermin (Increlex®)
2009	Andalusian Health Technology Assessment Area (AETSA)	[Utility of PET-FDG to assess response of breast, oesophagus and lung neoplasms. A systematic review of results after neoadjuvant therapy]
2009	Agency for Healthcare Research and Quality (AHRQ)	Treatment of overactive bladder in women
2009	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Information and communications technologies in mental health (Telepsychiatry)]
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Filgrastim (Ratiograstim®) for the treatment of neutropenia
2009	NIHR Health Technology Assessment programme	Prostate trials office (PROTO): co-ordinating trials of new technologies in the treatment of BPH
2009	Committee for New Health Technology Assessment (CNHTA)	[Cardio detect(h-FABP)]
2009	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Physical disease in schizophrenia: systematic review and analysis of hospital records]
2009	Andalusian Health Technology Assessment Area (AETSA)	[Endovascular treatment of cerebrovascular disease]
2009	Committee for New Health Technology Assessment (CNHTA)	[PDGFRA gene exon 12,18 mutation sequencing test]
2009	Agency for Healthcare Research and Quality (AHRQ)	Diagnosis and management of ductal carcinoma in situ (DCIS)
2009	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Transient elastography (Fibroscan) for the diagnosis of liver fibrosis: a systematic review and meta-analysis]
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[FDG-PET for avoidance of futile direct laryngoscopies under general anaesthesia with taking of biopsies in patients with suspicion on recurrent laryngeal carcinoma after radiotherapy]
2009	Andalusian Health Technology Assessment Area (AETSA)	[Endovascular treatment of cerebrovascular disease]
2009	HAYES, Inc.	AlloDerm regenerative tissue matrix (LifeCell Corp.) for postmastectomy breast reconstruction
2009	Committee for New Health Technology Assessment (CNHTA)	[Autologous noncultured epidermal cellular transplantation]
2009	Agency for Healthcare Research and Quality (AHRQ)	Treatment of common hip fractures
2009	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[The effectiveness of Positron Emission Tomography (PET) with 18FDG in breast cancer. A systematic review and meta-analysis]
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Etravirine (Intelence®) for the treatment of HIV-1 infected, antiretroviral treatment-experienced adults in combination with a boosted protease inhibitor and other antiretroviral medicinal products
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Foetal growth retardation at term: induction of labour or not? A comparison of maternal and neonatal outcome, maternal quality of life and costs (DIGITAT). The Disproportionate Intrauterine Growth Intervention Trial At Term (DIGITAT)]
2009	HAYES, Inc.	COL1A1 and COL1A2 gene testing for osteogenesis imperfecta types I to IV
2009	HAYES, Inc.	Hippotherapy for Neuromusculoskeletal Dysfunction
2009	Committee for New Health Technology Assessment (CNHTA)	[Anti-Heparin/Platelet Factor 4 antibody assey]
2009	Agency for Healthcare Research and Quality (AHRQ)	Vitamin D and calcium: a systematic review of health outcomes
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Ropinirole prolonged-release (Requip XL®) for the treatment of idiopathic Parkinson's disease
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis on depression]
2009	HAYES, Inc.	Continuous renal replacement therapy (CRRT) versus sustained low-efficiency daily dialysis (SLED) for adults with non-trauma-related acute renal failure
2009	Committee for New Health Technology Assessment (CNHTA)	[Intrastromal corneal ring surgery]
2009	Agency for Healthcare Research and Quality (AHRQ)	Outcomes of community health worker interventions
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Paricalcitol (Zemplar®) capsules for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency
2009	HAYES, Inc.	Liver transplantation for obese adults
2009	HAYES, Inc.	Continuous rotation of patients with acute respiratory distress syndrome (ARDS)
2009	Committee for New Health Technology Assessment (CNHTA)	[Allo skin graft]
2009	Agency for Healthcare Research and Quality (AHRQ)	Outcomes of genetic testing in adults with a history of venous thromboembolism
2009	NIHR Health Technology Assessment programme	Erlotinib for the treatment of relapsed non-small cell lung cancer
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Micafungin (Mycamine®) for the treatment of invasive candidiasis in adults and children
2009	The Swedish Council on Health Technology Assessment (SBU)	[Leukocytapheresis in inflammatory bowel disease (primarily ulcerative colitis)]
2009	HAYES, Inc.	Continuous subglottic secretion removal from the Hi-Lo endotracheal tube (Nellcor Puritan Bennett LLC) for prevention of ventilator-associated pneumonia (VAP)
2009	Committee for New Health Technology Assessment (CNHTA)	[PHEX gene, Mutation[Sequencing]]
2009	Agency for Healthcare Research and Quality (AHRQ)	Clinical utility of cancer family history collection in primary care
2009	Agency for Healthcare Research and Quality (AHRQ)	Screening for breast cancer: systematic evidence review update for the U.S. Preventive Services Task Force
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Bivalirudin (Angiox®) for the treatment of adult patients with acute coronary syndromes planned for urgent or early intervention
2009	Andalusian Health Technology Assessment Area (AETSA)	[Efficacy and safety of new oral antidiabetics. A systematic review of the literature and economic assessment]
2009	HAYES, Inc.	Impella recover LP 2.5 percutaneous ventricular assist device (Abiomed Inc.)
2009	Committee for New Health Technology Assessment (CNHTA)	[PRSS1 gene, Mutation[Sequencing]]
2009	Agency for Healthcare Research and Quality (AHRQ)	Complementary and alternative medicine in back pain utilization report
2009	Agency for Healthcare Research and Quality (AHRQ)	Screening for intermediate risk factors for coronary heart disease: systematic evidence synthesis
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tacrolimus (Advagraf®) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Prenatal diagnosis: MLPA or karyotyping]
2009	HAYES, Inc.	deCODE MI (deCODE diagnostics)
2009	HAYES, Inc.	Intravascular ultrasound (IVUS) for the assessment of peripheral artery disease (PAD) of the lower extremities
2009	Committee for New Health Technology Assessment (CNHTA)	[Peripheral nerve stimulation]
2009	Agency for Healthcare Research and Quality (AHRQ)	Maternal and neonatal outcomes of elective induction of labor
2009	Agency for Healthcare Research and Quality (AHRQ)	Screening for bilirubin encephalopathy
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Aripiprazole (Abilify®) tablets for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment